Acorda Therapeutics Receives and Responds to Third Point Letter.

M2 PRESSWIRE-26 February 2007-Headline Maker: Acorda Therapeutics Receives and Responds to Third Point Letter(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:26022007 Acorda Therapeutics (NASDAQ:ACOR) is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis, and related nervous system disorders.

The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, ...

Read the rest of this article with a Free Trial at HighBeam Research.